Mucinous carcinoma of the breast represents 1%-4% of all breast cancers. The World Health Organization classification divides this type of tumour into three different subtypes: mucinous carcinoma, mucinous carcinoma with tall columnar cells (mucinous cystadenocarcinoma and columnar cell mucinous carcinoma) and signet ring cell carcinoma. A 74-year-old woman presented a tumour with inflammatory features in the upper outer quadrant of her left breast, 7 cm in diameter. The core biopsy showed infiltrating ductal carcinoma of no specific type. The tumour-node-metastasis clinical staging was T4cN3M0 (Stage IIIC). She received neoadjuvant chemotherapy, underwent left mastectomy with radical axillary resection and subsequently received radiotherapy and chemotherapy. The histological examination of the surgical specimen revealed two solid tumors in the tail of Spence, which corresponded to adenocarcinoma with high columnar cells. The patient died 16 months after the diagnosis, suffering from pulmonary metastases and anterior chest wall infiltration. A review of the literature revealed only 21 reports of mucinous carcinoma of the breast with tall columnar cells, including our case. This is only the third time that the specific histological type of columnar cell mucinous carcinoma has been reported in the literature.
Desmoplastic small round-cell tumour is a very rare neoplasm, which usually arises from the abdominal or pelvic peritoneum of adolescents and young adults. Early diagnosis is difficult, because most tumours present with non-specific gastrointestinal symptoms after a long asymptomatic period. It is generally a very aggressive tumour, which grows rapidly with poor prognosis and an overall five-year survival rate of 15% despite multimodal treatment. Despite multiple treatment strategies, the management of desmoplastic small round-cell tumour still remains a clinical challenge and no consensus about a therapeutic protocol has been established. A 35-year-old man presented with mild abdominal pain, constipation and weight gain, and was eventually diagnosed with desmoplastic small round-cell tumour, which was shown to be limited to the abdomen. After incomplete debulking surgery, radiotherapy and chemotherapy, he developed multiple metastatic nodular foci in chest and the pleura and, unfortunately, he died due to disease progression.
HighlightsMorgagni hernias represents a rare subtype of diaphragmatic congenital hernias manifesting usually during early childhood.An innocuous or asymptomatic presentation render diagnosis of Morgagni hernias a challenging procedure.In our case, an adult female patient presented with a giant Morgagni hernia, initially diagnosed as a paraesophageal hernia.Early treatment of such cases is advised due to potential fatal complications. Laparoscopic surgery is considered the best approach.
as other platinum regimen in the favour Ad cohort (43% vs 46%), whereas poorer response in the favour SqCC (0% vs 50%) and NOSnull (0% vs 24%) cohort. Although patients to be received pemetrexed containing platinum regimen compared to those to be received other platinum regimen demonstrated a trend toward good PFS in favour Ad group, there were no statistically differences. Conclusion: This study made clear chemo-responsiveness, the expression frequency of driver mutation and prognosis in NSCLC favour Ad, SqCC and NOS-null. These findings support that histological subtyping in biopsy specimen by IHC would be mandatory to archive appropriate therapy.Background: Currently, tumor size of invasive mucinous adenocarcinoma such as invasive mucinous adenocarcinoma (IMA) is defined by the spread of mucinous component regardless of the existence of tumor cells. The aim of this study is to investigate the prognostic impact of the size of invasive lesion, actual tumor spread, mucinous component in IMA. Method: Consecutive 19 patients with pN0M0 IMAs which were completely resected between Jan. 2009 and Dec 2015 were retrospectively analyzed. Invasive size (IS), actual tumor size (aTS), and mucinous tumor size (mTS, current T factor) were measured on the identical pathological section, and radiological tumor size (rTS) was also recorded by thorax computed tomography. The prognostic value for postoperative recurrence was evaluated by area under the receiver-operating characteristic (ROC) curves and compared by DeLong's test. Result: Based on mTS, study population included 2 patients T1a, 3 with T1b, 7 with T1c, 4 with T2a, and 3 with T2b. Median age, follow-up, IS, aTS, mTS, and rTS were 75 years, 39 monts, 11mm, 25mm, 26mm and 30mm, respectively. During follow-up, 1 mortality and 3 recurrences were observed. The area under the ROC curves for IS, aTS, mTS, and rTS were 0.833 (p¼0.074)、0.979 (p¼0.01)、1.0 (p¼0.007)、0.958(p¼0.014). The mTS showed no significant difference compared to IS, aTS or rTS. Conclusion: In IMA, aTS and mTS might have prognostic value for recurrence. Prospective study with larger population would be necessary to validate the results.Background: Tumor grade is an important factor of cancer outcome. Systematic inflammation has been associated with tumorigenesis and tumor aggressiveness and prognosis in several human malignancies. Cancer cells create an inflammatory peritumoral microenviroment by releasing a number of cytokines. Method: In total, 100 patients (88 males) with histologically proven NSCLC and no signs of active infection were evaluated. Tumor grade was examined and systematic inflammatory response was assessed by circulating levels of C-reactive protein (CRP), albumin, ferritin, transferring and the modified Glasgow Prognostic Score (mGPS). Patients were followed up and survival data were subsequently collected. Associations with clinicopathological, histological parameters and patients' survival were studied. Result: Histological grade was associated with tumor size, the presence of pathologica...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.